Coronado Biosciences Signs Binding Terms of Agreement to Enter Into Collaboration for Development of CNDO-201

by Matthew Kennedy, Benzinga Staff Writer
December 22, 2011 2:00 PM | 11 seconds read |
Coronado Biosciences, Inc. CNDO, today announced a binding Terms of Agreement with Dr. Falk Pharma GmbH and OvaMed GmbH to collaborate in the development of CNDO-201, or Trichuris suis ova, for Crohn's disease.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!